1. Home
  2. SCLXW

as of 02-05-2026 3:41pm EST

$0.14
$0.01
-7.77%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Founded: N/A Country:
United States
United States
Employees: 30 City: PALO ALTO
Market Cap: N/A IPO Year: N/A
Target Price: N/A AVG Volume (30 days): 4.0K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.78 EPS Growth: N/A
52 Week Low/High: $0.18 - $0.18 Next Earning Date: 03-07-2025
Revenue: $55,152,000 Revenue Growth: 22.02%
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: